Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ADAPY, Q2 2026
No superinvestor reported holding ADAPY at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Adaptimmune Therapeutics PLC insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2025 (view filing)5:00 PM ET | Sep 2 | 1 day | Wood GavinChief Financial Officer | SSaleOrdinary Shares with a nominal value of GBP0.001 per share | −96.0K | $0.0099 | −$950.4 | −100.0%0 after | |
| Aug 29, 2025 (view filing)6:25 PM ET | Aug 28 | 1 day | Bertrand William C JRChief Operating Officer | SSaleOrdinary Shares with a nominal value of GBP0.001 per share | −207.0K | $0.0101 | −$2.09K | −17.3%986.4K after | |
| Aug 19, 2025 (view filing)7:07 PM ET | Aug 15-18 | 4 days | Behbahani AliDirector | SSaleOrdinary Shares with a nominal value of 0.001 GBP per share | −19.5M | $0.0118 | −$229.2K | −100.0%0 after | 2 lots |
| Jul 30, 2025 (view filing)6:20 PM ET | Jul 28-30 | 2 days | EcoR1 Capital, LLC10% Owner | SSale | −64.1M | $0.1076 | −$6.89M | −39.0%100.4M after | 3 lots |
| Jan 17, 2025 (view filing) | Jan 17 | Same day | Norry ElliotChief Medical Officer | SSaleAmerican Depositary Shares representing Ordinary Shares | −5.58K | $0.58 | −$3.24K | −42.6%7.51K after | |
| Jan 17, 2025 (view filing) | Jan 17 | Same day | Lunger JohnChief Patient Supply Officer | SSaleAmerican Depositary Shares representing Ordinary Shares | −5.58K | $0.58 | −$3.24K | −42.6%7.51K after | |
| Jan 17, 2025 (view filing) | Jan 17 | Same day | Bertrand William C JRChief Operating Officer | SSaleAmerican Depositary Shares representing Ordinary Shares | −5.58K | $0.58 | −$3.24K | −42.6%7.51K after | |
| Jan 17, 2025 (view filing) | Jan 17 | Same day | Rawcliffe AdrianChief Executive Officer | SSaleAmerican Depositary Shares representing Ordinary Shares | −30.6K | $0.58 | −$17.7K | −40.8%44.3K after | |
| Jan 15, 2025 (view filing) | Jan 13-15 | 2 days | Rawcliffe AdrianChief Executive Officer | SSaleAmerican Depositary Shares representing Ordinary Shares | −59.6K | $0.5802 | −$34.6K | −58.9%41.6K after | 3 lots |
| Jan 15, 2025 (view filing) | Jan 15 | Same day | Piccina CintiaChief Commercial Officer | SSaleAmerican Depositary Shares representing Ordinary Shares | −13.0K | $0.57 | −$7.40K | −41.4%18.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Adaptimmune Therapeutics PLC at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding ADAPY in 13F filings for Q2 2026.